Bayer's novel anticoagulant Xarelto approved in EU

Published: 2008-10-13 06:57:00

Updated: 2008-10-13 06:57:00

The European Commission has granted marketing approval for Xarelto (rivaroxaban), a novel anticoagulant taken as one tablet, once-daily, for the prevention of venous blood clots in adult patients undergoing elective (planned) hip or knee replacement surgery. Bayer HealthCare will start launching the product in the EU member states from next year.

"The successful development program of Xarel...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.